Search Results
206 items found for "Systemic treatment"
- Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European ...
receptor inhibitor, in combination with a rituximab or cyclophosphamide regimen, indicated for the treatment
- Discovery of 3(2-aminoethyl)-thiazolidine-2,4-diones as a novel chemotype of sigma-1 receptor ligand
Therefore, S1R ligands possess a variety of potential clinical applications with a great interest in the treatment
- A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation
numbers of people with excess body weight, the MC4R has become a target of interest in the search of treatment
- 📰 GPCR Weekly News, July 1 to 7, 2024
and disrupt downstream intracellular signaling Therapeutic potential of allosteric modulators for the treatment diseases: pharmacotherapeutic development updates Targeting G protein-coupled receptors for heart failure treatment
- 📰 GPCR Weekly News, June 10 to 16, 2024
ventricular hiPSC-cardiomyocytes to GPCR and ion channel targeting compounds: A microphysiological system
- Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc. has...
program will enable centers in Japan to be included in a potential global development of ADX71149 for the treatment
- Chemical signaling regulates axon regeneration via the GPCR-Gqα pathway in Caenorhabditis elegans
Therefore, the ascaroside signaling system provides a unique example of a signaling molecule that regulates
- A Chemical Biology Toolbox Targeting the Intracellular Binding Site of CCR9: Fluorescent Ligands ...
intracellular C-C chemokine receptor type 9 (CCR9) antagonist and previous phase III clinical candidate for the treatment
- Effect Delta-9-tetrahydrocannabinol and cannabidiol on milk proteins and lipid levels in HC11 cells
In addition, co-treatment of a CB2 antagonist with THC, and a CB2 agonist with CBD, reversed the impact
- 📰 GPCR Weekly News, February 20 to 26, 2023
Drugs, and more Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment
- Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin ...
therapy but the disease recurs as incurable castration-resistant prostate cancer (CRPC), requiring new treatment
- 📰 GPCR Weekly News, October 2 to 8, 2023
related behaviors Methods & Updates in GPCR Research Functional GPCR expression in eukaryotic LEXSY system
- Enhanced membrane binding of oncogenic G protein αqQ209L confers resistance to inhibitor YM-254890
Treatment of cells with YM failed to inhibit signaling by these PM-restricted αqQ209L.
- PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design
Pc(4-4) may become a promising candidate for future therapeutic cancer treatment."
- GPR3 expression in retinal ganglion cells contributes to neuron survival and accelerates axonal...
when GPR3 was upregulated in RGCs, and the effect was further augmented when combined with zymosan treatment
- Self-docking and cross-docking simulations of G protein-coupled receptor-ligand complexes
Their abundance and role in nearly all physiological systems make GPCR the largest protein family targeted
- 📰 GPCR Weekly News - January 2 to 8, 2023
GPCR Signaling Measurement and Drug Profiling with an Automated Live-Cell Microscopy System.
- 📰 GPCR Weekly News
Therapeutic potential of allosteric modulators for the treatment of gastrointestinal motility disorders Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment
- Chemogenetic stimulation of the G i pathway in astrocytes suppresses neuroinflammation
activation of the astrocytic Gi pathway attenuated intracellular calcium transients triggered by LPS treatment
- Novel interaction between neurotrophic factor-α1/carboxypeptidase E and serotonin receptor, 5-HTR1E,
Treatment of 5-HTR1E stable cells with NF-α1/CPE increased pERK 1/2 and pCREB levels which prevented
- Platelets in the NETworks interweaving inflammation and thrombosis
A better understanding of the underlying molecular mechanisms and the identification of treatment targets
- Ode to GPCRs
James Whyte Black, and Gertrude Belle Elion for their discoveries of important principles for drug treatment Richard Kandel, Arvid Carlsson, and Paul Greengard for research on signal transduction in the nervous system Dopamine exerts its action in the human nervous system via dopamine receptors and human trace amine-associated
- Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of ...
binding and endocytosis, and a very high basal rate of degradation that is not protected by antagonist treatment
- A role for BET proteins in regulating basal, dopamine-induced and cAMP/PKA-dependent ...
Finally, we report that JQ1 treatment downregulated expression of many GPCRs and also impaired ERK1/2
- 📰 GPCR Weekly News, June 19 to 25, 2023
GPCR Binders, Drugs, and more Molecular Characterization of Two Wamide Neuropeptide Signaling Systems
- 📰 GPCR Weekly News, January 23 to 29, 2023
GPCR Signaling Measurement and Drug Profiling with an Automated Live-Cell Microscopy System.
- 📰 GPCR Weekly News, June 12 to 18, 2023
Portfolio with Granted Patent in Japan Proteros Biostructures GmbH Revolutionizes Metabolic Disorder Treatments
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
Twice-daily treatment with mOB-004 dose-dependently suppressed monocyte infiltration into the peritoneum to rapidly and efficiently advance a diversified portfolio of GPCR-targeted drug candidates for the treatment 11. https://doi.org/10.1126/scitranslmed.aav5519 · Demonstration of the in vivo efficacy of a systemically